Edition:
United States

Depomed Inc (DEPO.OQ)

DEPO.OQ on NASDAQ Stock Exchange Global Select Market

6.79USD
23 Apr 2018
Change (% chg)

$0.11 (+1.65%)
Prev Close
$6.68
Open
$6.71
Day's High
$6.99
Day's Low
$6.71
Volume
336,057
Avg. Vol
347,898
52-wk High
$12.49
52-wk Low
$4.32

Latest Key Developments (Source: Significant Developments)

Depomed Inc Files For Mixed Shelf Of Up To $300 Million‍​
Friday, 2 Mar 2018 05:14pm EST 

March 2 (Reuters) - Depomed Inc ::DEPOMED INC FILES FOR MIXED SHELF OF UP TO $300 MILLION - SEC FILING ‍​.  Full Article

Depomed Reports Q4 GAAP Loss Per Share $0.52
Tuesday, 27 Feb 2018 04:03pm EST 

Feb 27 (Reuters) - Depomed ::ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 GAAP LOSS PER SHARE $0.52.Q4 REVENUE $94 MILLION.INC - ‍Q4 2017 ENDING CASH AND MARKETABLE SECURITIES WERE $128 MILLION​.  Full Article

Depomed Announces Nucynta® Commercialization Agreement With Collegium Pharmaceutical
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Depomed Inc ::DEPOMED ANNOUNCES NUCYNTA® COMMERCIALIZATION AGREEMENT WITH COLLEGIUM PHARMACEUTICAL.DEPOMED INC - RELOCATION OF COMPANY HEADQUARTERS MID-2018.DEPOMED INC - TRANSACTION IS IMMEDIATELY ACCRETIVE AND IMPROVES 2018 EBITDA OUTLOOK.DEPOMED - PLANS TO RELOCATE ITS CORPORATE HEADQUARTERS FROM NEWARK, SOMETIME IN MID-2018 & IS CURRENTLY EVALUATING POTENTIAL MIDWEST & EAST COAST LOCATIONS.DEPOMED INC - COMPANY WILL REDUCE ITS STAFF BY 40% TO APPROXIMATELY 70 EMPLOYEES AND HEADQUARTERS OFFICE SPACE REQUIREMENT BY 50%.DEPOMED INC - EXPECTS TO SAVE APPROXIMATELY $10 MILLION ANNUALLY AS A RESULT OF HEADQUARTERS RESTRUCTURING AND RELOCATION.DEPOMED INC - WILL ELIMINATE ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING ON NUCYNTA.DEPOMED INC - BY ELIMINATING ITS PAIN SALESFORCE AND CEASE ALL BRAND SPENDING CO TO REDUCE SG&A EXPENSES BY ABOUT $70 MILLION ON AN ANNUAL BASIS.DEPOMED INC - UNDER TERMS OF AGREEMENT, COLLEGIUM WILL COMMERCIALIZE BOTH NUCYNTA EXTENDED RELEASE AND NUCYNTA IMMEDIATE RELEASE.DEPOMED INC - DEPOMED WILL RECEIVE A ROYALTY RATE ON ALL NUCYNTA REVENUES BASED ON CERTAIN NET SALES THRESHOLDS.  Full Article

Collegium To License Rights To Commercialize Nucynta Franchise
Monday, 4 Dec 2017 04:30pm EST 

Dec 4 (Reuters) - Collegium Pharmaceutical Inc ::COLLEGIUM TO LICENSE RIGHTS TO COMMERCIALIZE NUCYNTA FRANCHISE.COLLEGIUM PHARMACEUTICAL INC - DEAL IS IMMEDIATELY ACCRETIVE.COLLEGIUM PHARMACEUTICAL INC - ENTERED INTO A DEFINITIVE COMMERCIALIZATION AGREEMENT WITH DEPOMED.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY A MINIMUM ANNUAL LICENSE FEE OF $135.0 MILLION PAID QUARTERLY IN ARREARS.COLLEGIUM PHARMACEUTICAL - FOR FIRST FOUR YEARS OF AGREEMENT, COLLEGIUM WILL ALSO PAY DOUBLE-DIGIT ROYALTIES ON NET SALES ABOVE $233.0 MILLION PER YEAR.COLLEGIUM PHARMACEUTICAL - AFTER 12 MONTHS, CO MAY TERMINATE AGREEMENT WITH TWELVE MONTHS' NOTICE AND PAYMENT OF A $25.0 MILLION TERMINATION FEE.COLLEGIUM PHARMACEUTICAL INC - AFTER FOUR YEARS OF AGREEMENT, COLLEGIUM WILL PAY DOUBLE-DIGIT ROYALTIES ON ALL NET SALES.COLLEGIUM PHARMACEUTICAL INC - TRANSACTION HAS BEEN APPROVED BY COLLEGIUM'S AND DEPOMED'S BOARD OF DIRECTORS.COLLEGIUM PHARMACEUTICAL INC - EXPECTS TO SUPPORT NUCYNTA FRANCHISE WITH ITS EXISTING RETAIL AND HOSPITAL FIELD FORCES.COLLEGIUM PHARMACEUTICAL INC - WILL RECEIVE AN EXCLUSIVE SUBLICENSE TO COMMERCIALIZE NUCYNTA AND NUCYNTA ER IN UNITED STATES.  Full Article

Depomed announces Q3 loss of $0.25 per share
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Depomed Inc :Depomed inc sees ‍2017 total revenue $375 to $380 million​.Sees ‍2017 non-gaap adjusted ebitda $104 to $109 million​.Depomed inc sees ‍2017 non-gaap total revenue $380 to $385 million​.Q3 adjusted non-GAAP earnings per share $0.14.Q3 GAAP loss per share $0.25.Q3 revenue $95 million versus i/b/e/s view $99.1 million.Q3 earnings per share view $0.11 -- Thomson Reuters I/B/E/S.FY 2017 revenue view $396.3 million -- Thomson Reuters I/B/E/S.Company will experience temporary outages of certain strengths of nucynta er in q4​.Based on current inventory, manufacturer's potential ability to produce nucynta er supply, expect magnitude of outages to be less than $10 million​.Company believes it has an adequate inventory of gralise, which is manufactured in Puerto Rico​.Does not anticipate material disruption to nucynta ir supply from new third party manufacturer in the u.s.​.  Full Article

Depomed and Slán Medicinal Holdings announce strategic asset transactions
Tuesday, 7 Nov 2017 04:00pm EST 

Nov 7 (Reuters) - Depomed Inc :Depomed and Slán Medicinal Holdings Ltd announce strategic asset transactions.Depomed Inc - ‍Slán Medicinal Holdings limited to acquire Lazanda from Depomed​.Depomed - co to buy from Slán rights to market specialty drug, cosyntropin in united states and divest its Lazanda nasal spray cii to Slán​.Depomed - intends to seek approval for cosyntropin in u.s., subsequent to approval co, Slán to share in net sales of Cosyntropin for 10-year period​.  Full Article

PDL Biopharma announces settlement agreement with Valeant
Monday, 30 Oct 2017 07:00am EDT 

Oct 30 (Reuters) - PDL Biopharma Inc :PDL Biopharma announces settlement agreement with Valeant.PDL Biopharma - ‍Valeant to pay a one-time, lump-sum payment of $13.0 million as part of settlement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment will be transferred to co pursuant to terms of Depomed royalty agreement.PDL Biopharma - ‍Valeant's one-time, lump-sum payment to co will not recognized as revenue by Depomed​.PDL - ‍depomed, co to release Valeant from claims against it arising from royalty audit, Valeant's obligation to pay royalties during audit period​.PDL Biopharma Inc- ‍valeant will release Depomed, co from all claims against them as a result of audit and/or litigation​.PDL - ‍entered into settlement with Valeant that resolves matters relating to "alleged underpayment of royalties by Valeant"​.  Full Article

Depomed ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​
Tuesday, 10 Oct 2017 07:30am EDT 

Oct 10 (Reuters) - Depomed Inc : :Says ‍provides information on impact of hurricane Maria to supply of NUCYNTA ER​.Depomed Inc - ‍most recent assessment that co has received from manufacturer of NUCYNTA ER indicates that facility in Puerto Rico suffered minor damage.Depomed Inc - ‍company's Q3 product revenue was negatively impacted by approximately $2 to $3 million​ due to hurricane Maria.Depomed Inc says site leaders at facility in Puerto Rico​ are working to return facility to full operation.Depomed Inc - ‍expects its Q4 product revenue may be negatively impacted by less than $10 million​.Says ‍NUCYNTA ER is manufactured in Puerto Rico by company's third party manufacturing partner​.Depomed - ‍co will provide an update to its full year 2017 financial guidance and on NUCYNTA ER supply situation during its Q3 conference call in early November​.Depomed - ‍does not currently anticipate, based on information available to it at this time, any material disruption to supply of NUCYNTA IR or Gralise​.  Full Article

Armistice Capital LLC reports 6.4 pct passive stake in Depomed Inc
Friday, 18 Aug 2017 03:24pm EDT 

Aug 18 (Reuters) - Depomed Inc ::Armistice Capital LLC reports 6.4 percent passive stake in Depomed Inc as on August 8, 2017 - SEC filing‍​‍​.  Full Article

Depomed Q2 loss per share $0.43
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Depomed Inc :Depomed announces second quarter 2017 financial results.Q2 adjusted non-GAAP earnings per share $0.08.Q2 GAAP loss per share $0.43.Q2 revenue $100 million versus I/B/E/S view $99.4 million.Q2 earnings per share view $0.09 -- Thomson Reuters I/B/E/S.Depomed Inc sees 2017 total revenue (GAAP) $395 to $410 million.Depomed Inc sees 2017 total revenue (non-GAAP) $400 to $415 million.Depomed Inc sees 2017 non-gaap adjusted EBITDA $107 to $117 million.FY 2017 revenue view $417.8 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Depomed Appoints Stan Bukofzer As Chief Medical And Scientific Officer

* DEPOMED ANNOUNCES THE APPOINTMENT OF STAN BUKOFZER, M.D. AS SENIOR VICE PRESIDENT AND CHIEF MEDICAL AND SCIENTIFIC OFFICER Source text for Eikon: Further company coverage: